Cadila Healthcare rises on getting USFDA’s nod for Amiloride Hydrochloride Tablets

11 Aug 2015 Evaluate

Cadila Healthcare is currently trading at Rs. 1915.00, up by 18.20 points or 0.96% from its previous closing of Rs. 1896.80 on the BSE.

The scrip opened at Rs.1900.85 and has touched a high and low of Rs.1935.00 and Rs.1897.75 respectively. So far 9475 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2045.00 on 17-Jul-2015 and a 52 week low of Rs. 1075.45 on 12-Aug-2014.

Last one week high and low of the scrip stood at Rs. 1960.00 and Rs. 1846.00 respectively. The current market cap of the company is Rs. 39225.72 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 15.04% and 10.17% respectively.

Zydus Cadila has received the final approval from the USFDA to market Amiloride Hydrochloride Tablets USP, 5 mg. The drug falls in the diuretics segment. The group now has 101 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

913.35 -1.30 (-0.14%)
01-Jan-2026 13:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.30
Dr. Reddys Lab 1250.00
Cipla 1500.35
Zydus Lifesciences 913.35
Lupin 2099.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×